MANKIND
Invest Now

Mankind Pharma Share Price
₹2,414.20 +10.5 (0.44%)
27 Mar, 2025 14:48
Start SIP in
MANKIND
Performance
- Low
- ₹2,373
- High
- ₹2,434
- 52 Week Low
- ₹1,901
- 52 Week High
- ₹3,055
- Open Price₹2,403
- Previous Close₹2,404
- Volume256,408
Investment Returns
- Over 1 Month + 3.32%
- Over 3 Month -17.03%
- Over 6 Month -9.88%
- Over 1 Year + 7.53%
Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!
Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 48.8
- PEG Ratio
- 2.8
- Market Cap Cr
- 99,605
- P/B Ratio
- 9.4
- Average True Range
- 91.57
- EPS
- 49.48
- Dividend Yield
- 0
- MACD Signal
- -48.32
- RSI
- 56.56
- MFI
- 72.85
Mankind Pharma Financials
Mankind Pharma Technicals
EMA & SMA
Current Price
₹2,414.20
+
10.5
(0.44%)

-
- Bearish Moving Average 4
-
- Bullish Moving Average 12
- 20 Day
- ₹2,311.09
- 50 Day
- ₹2,395.58
- 100 Day
- ₹2,459.25
- 200 Day
- ₹2,417.72
Resistance and Support
2402.37
- R3 2,523.93
- R2 2,482.97
- R1 2,443.33
- S1 2,362.73
- S2 2,321.77
- S3 2,282.13
Mankind Pharma Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-01-23 | Quarterly Results | |
2024-11-05 | Quarterly Results | |
2024-07-31 | Quarterly Results | |
2024-05-15 | Audited Results & Others | To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
2024-01-31 | Quarterly Results |
Mankind Pharma F&O
About Mankind Pharma
- NSE Symbol
- MANKIND
- BSE Symbol
- 543904
- ISIN
- INE634S01028
Similar Stocks to Mankind Pharma
Mankind Pharma FAQs
Mankind Pharma share price is ₹2,414 As on 27 March, 2025 | 14:34
The Market Cap of Mankind Pharma is ₹99604.7 Cr As on 27 March, 2025 | 14:34
The P/E ratio of Mankind Pharma is 48.8 As on 27 March, 2025 | 14:34
The PB ratio of Mankind Pharma is 9.4 As on 27 March, 2025 | 14:34
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.